OBJECTIVE: This article reviews the published studies dealing with the influence of cigarette smoking on metabolic changes and effectiveness of drugs used in the systemic chemotherapy of the lung cancer. METHODS: The literature search of interactions between cigarette smoking and drugs used for lung cancer was carried out. The abstracted data mostly involved some induction of key drug-metabolizing enzymes of cytochrome CYP1A1/2, CYP2D6, CYP3A4 and isoforms of UDP-glucuronosyltransferase. RESULTS: Metabolic changes are important both in the non-chemotherapy and for the drugs used in the chemotherapy. They can change pharmacokinetic and pharmacodynamic effects of drugs. Primarily, we addressed potential differences in drug effects on smokers and non-smokers. The increased clearance of erlotinib and irinotecan may have impact on effectiveness of the lung cancer therapy. The effects of taxanes and gemcitabine are more complex. CONCLUSION: The evaluated studies show that continued smoking after lung cancer diagnosis is related to poor prognosis, reduced survival, risk of second primary malignancies, and increased cancer recurrence. Of particular importance is the deterioration in the quality of life and an increased incidence of the adverse drug reactions in smokers. The patient's cigarette smoking history should be considered carefully and smoking cessation must be taken into account.

Department of Pharmacology 1st Faculty of Medicine Charles University and General University Hospital Prague Czech Republic

Institute for Postgraduate Medical Education Prague Czech Republic

Literatura

000      

00000naa a2200000 a 4500

001      

bmc20004535

003      

CZ-PrNML

005      

20200610103327.0

007      

ta

008      

200511s2020 xr f 000 0|eng||

009      

AR

024    7_

$a 10.21101/cejph.a5620 $2 doi

035    __

$a (PubMed)32228818

040    __

$a ABA008 $b cze $d ABA008 $e AACR2

041    0_

$a eng

044    __

$a xr

100    1_

$a Perlík, František, $d 1940-2020 $7 nlk20040147478 $u Department of Pharmacology, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic; Institute for Postgraduate Medical Education, Prague, Czech Republic

245    10

$a Impact of smoking on metabolic changes and effectiveness of drugs used for lung cancer / $c F. Perlík

504    __

$a Literatura

520    9_

$a OBJECTIVE: This article reviews the published studies dealing with the influence of cigarette smoking on metabolic changes and effectiveness of drugs used in the systemic chemotherapy of the lung cancer. METHODS: The literature search of interactions between cigarette smoking and drugs used for lung cancer was carried out. The abstracted data mostly involved some induction of key drug-metabolizing enzymes of cytochrome CYP1A1/2, CYP2D6, CYP3A4 and isoforms of UDP-glucuronosyltransferase. RESULTS: Metabolic changes are important both in the non-chemotherapy and for the drugs used in the chemotherapy. They can change pharmacokinetic and pharmacodynamic effects of drugs. Primarily, we addressed potential differences in drug effects on smokers and non-smokers. The increased clearance of erlotinib and irinotecan may have impact on effectiveness of the lung cancer therapy. The effects of taxanes and gemcitabine are more complex. CONCLUSION: The evaluated studies show that continued smoking after lung cancer diagnosis is related to poor prognosis, reduced survival, risk of second primary malignancies, and increased cancer recurrence. Of particular importance is the deterioration in the quality of life and an increased incidence of the adverse drug reactions in smokers. The patient's cigarette smoking history should be considered carefully and smoking cessation must be taken into account.

650    _2

$a antitumorózní látky $x farmakokinetika $x terapeutické užití $7 D000970

650    _2

$a lidé $7 D006801

650    _2

$a nádory plic $x farmakoterapie $7 D008175

650    _2

$a kouření $x metabolismus $7 D012907

650    _2

$a výsledek terapie $7 D016896

655    _2

$a časopisecké články $7 D016428

655    _2

$a přehledy $7 D016454

773    0_

$w MED00001083 $t Central European journal of public health $x 1210-7778 $g Roč. 28, č. 1 (2020), s. 53-58

856    41

$u https://pubmed.ncbi.nlm.nih.gov/32228818 $y Pubmed

910    __

$a ABA008 $b B 1829 $c 562 $y p $z 0

990    __

$a 20200511 $b ABA008

991    __

$a 20200610103324 $b ABA008

999    __

$a ok $b bmc $g 1528536 $s 1094583

BAS    __

$a 3

BAS    __

$a PreBMC

BMC    __

$a 2020 $b 28 $c 1 $d 53-58 $e 20200330 $i 1210-7778 $m Central European Journal of Public Health $n Cent. Eur. J. Public Health $x MED00001083

LZP    __

$b NLK118 $a Pubmed-20200511